Phase II pilot study of induction erlotinib therapy in patients with resectable non-small cell lung cancer to select postoperative adjuvant therapy

被引：0
|
作者：
Lee, Dae Ho
Hong, Yong Sang
Kim, Tae Won
Jung, Kyung Hae
Kim, Sang -We
Suh, Cheolwon
Lee, Jung -Shin
Kim, Heung Tae
机构：
来源：
MOLECULAR CANCER THERAPEUTICS | 2009年 / 8卷 / 12期
关键词：
D O I：
10.1158/1535-7163.TARG-09-C41
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
C41
引用
收藏
页数：3
相关论文
共 50 条
  • [1] A phase II study of atezolizumab as neoadjuvant and adjuvant therapy in patients (pts) with resectable non-small cell lung cancer (NSCLC).
    Owen, Dwight Hall
    Bunn, Paul A.
    Johnson, Bruce E.
    Kwiatkowski, David J.
    Kris, Mark G.
    Wistuba, Ignacio Ivan
    Gandhi, Mayank
    Phan, See
    Shames, David S.
    Schulze, Katja
    Yu, Wei
    Aisner, Dara
    Chaft, Jamie E.
    Garon, Edward B.
    Lee, Jay M.
    Minna, John D.
    Rusch, Valerie W.
    Reckamp, Karen L.
    Wozniak, Antoinette J.
    Carbone, David P.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [2] The role of induction therapy for resectable non-small cell lung cancer
    Stinchcombe, Thomas E.
    Socinski, Mark A.
    DRUGS, 2007, 67 (03) : 321 - 332
  • [3] Induction or neoadjuvant therapy in resectable non-small cell lung cancer
    Langer, CJ
    SEMINARS IN ONCOLOGY, 1999, 26 (05) : 34 - 39
  • [4] Erlotinib as standard adjuvant therapy for resectable EGFR mutation-positive non-small cell lung cancer
    Tanaka, Satomi
    Uchino, Junji
    TRANSLATIONAL LUNG CANCER RESEARCH, 2019, 8 : S369 - S372
  • [5] The Role of Induction Therapy for Resectable Non-Small Cell Lung Cancer
    Thomas E. Stinchcombe
    Mark A. Socinski
    Drugs, 2007, 67 : 321 - 332
  • [6] Phase II study of chemoradiation therapy and erlotinib for stage Ill non-small cell lung cancer
    Komaki, Ritsuko U.
    Wistuba, Ignacio
    Tang, Xi Ming
    Meyn, Raymond E.
    Lee, J. Jack
    Wei, Xiong
    Allen, Pamela K.
    O'Reilly, Michael S.
    Welsh, James
    Hong, Wuan Ki
    CANCER RESEARCH, 2011, 71
  • [7] A Phase II Study of Atezolizumab as Neoadjuvant and Adjuvant Therapy in Patients (pts) with Resectable Non Small Cell Lung Cancer (NSCLC)
    Owen, Dwight
    Bunn, Paul, Jr.
    Johnson, Bruce
    Kwiatkowski, David
    Kris, Mark
    Wistuba, Ignacio
    Gandhi, Mayank
    Phan, See
    Shames, David
    Schulze, Katja
    Bernaards, Coen
    Aisner, Dara
    Chaft, Jamie
    Gainor, Justin
    Lee, Jay
    Minna, John
    Mino-Kenudson, Mari
    Garcia-Prieto, Celia
    Rusch, Valerie
    Sabichi, Anita
    Villaruz, Liza
    Wozniak, Antoinette
    Carbone, David
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1082 - S1082
  • [8] Operable non-small cell lung cancer: induction therapy, adjuvant therapy, or both?
    Agrafiotis, Apostolos C.
    Van Schil, Paul E.
    JOURNAL OF THORACIC DISEASE, 2023, 15 (07) : 3519 - 3521
  • [9] Erlotinib in First-line Therapy for Non-small Cell Lung Cancer: A Prospective Phase II Study
    Choi, Dae Ro
    Lee, Dae Ho
    Choi, Chang-Min
    Kim, Sang-We
    Suh, Cheolwon
    Lee, Jung-Shin
    ANTICANCER RESEARCH, 2011, 31 (10) : 3457 - 3462
  • [10] A prospective phase II study of induction erlotinib therapy in stage IIIA-N2 non-small cell lung cancer
    Zhong, Wenzhao
    Yang, Xuening
    Liao, Riqiang
    Nie, Qiang
    Su, Jian
    Chen, Zhihong
    Zhang, Xuchao
    An, Shejuan
    Zhou, Qing
    Yang, Jinji
    Wu, Yi Long
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
12345